Amyloid cardiomyopathy.

Area of Science:

• Cardiology
• Hematology
• Genetics

Background:

• Cardiac amyloidosis is a progressive condition characterized by amyloid fibril deposition in organs, leading to organ failure.
• Common forms include immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), with ATTR arising from gene variants or wild-type protein.
• Cardiac involvement is a frequent and serious manifestation of these amyloidosis types.

Purpose of the Study:

• To emphasize the critical need for precise diagnostic assessment in cardiac amyloidosis.
• To highlight the importance of early diagnosis for initiating timely and effective treatment.
• To review current therapeutic strategies for different types of cardiac amyloidosis.

Main Methods:

• Comprehensive diagnostic evaluation including laboratory tests, electrocardiography, echocardiography, cardiac MRI, biopsy, and bone scintigraphy.
• Assessment of amyloid type to guide treatment decisions.
• Review of treatment approaches for AL amyloidosis and hereditary ATTR amyloidosis.

Main Results:

• Accurate diagnosis is mandatory for defining amyloid type and initiating appropriate therapy.
• Treatment encompasses symptomatic heart failure management and addressing the underlying disease.
• Significant therapeutic advances include RNA silencers for ATTR amyloidosis, though amyloid removal from tissue remains a challenge.

Conclusions:

• Early diagnosis of cardiac amyloidosis is paramount for optimizing treatment efficacy.
• While treatments exist for underlying causes and symptoms, no therapy currently removes deposited amyloid.
• Continued research and early detection are key to improving outcomes for patients with cardiac amyloidosis.